Luke Halpern, Associate Editor

Adding semaglutide to existing regimens in older adults with inadequately controlled T2D significantly reduced HbA1c, fasting blood glucose, body weight, and blood pressure.

John Buse, MD, PhD, breaks down the 2026 American Diabetes Association (ADA) hyperglycemia guidance update, including earlier glucagon-like peptide-1 (GLP-1) receptor agonist and sodium-glucose cotransporter 2 (SGLT-2) inhibitor use and a broader holistic care framework.

Jillian Fetzner, MSN, APRN-CNP, described how integrating pharmacists into a collaborative practice agreement processed 3750 diabetes refill requests without provider involvement.

Dave Dixon, PharmD, breaks down the key cardiovascular and kidney risk management updates in the 2026 ADA Standards of Care and what they mean for pharmacy practice.

As retatrutide moves toward FDA submission, Jennifer Goldman, PharmD, breaks down the TRIUMPH-1 data—and what they mean for patient selection, dose escalation counseling, and positioning within the antiobesity pipeline.

With no new kidney-protective therapies approved in T1D for over 3 decades, experts break down the clinical significance of finerenone's FDA priority review and what pharmacists need to know.

A cross-sectional analysis of nearly 30,000 US adults found that economic instability, food insecurity, limited education, and poor social context each independently elevated the odds of advanced cardiovascular-kidney-metabolic (CKD) syndrome—but not equally across all groups.

As Novo Nordisk transitions patients from Rybelsus to newer, higher-efficacy oral semaglutide formulations, pharmacists are on the front lines of counseling, dosing clarification, and adverse effect management.

The approval ends a decades-long gap in care for patients with chronic hepatitis delta virus (HDV) infection, a serious and life-threatening coinfection with hepatitis B that can rapidly progress to cirrhosis, liver cancer, and liver failure.

A board-certified psychiatric pharmacist breaks down how systemic fragmentation, access barriers, and policy gaps are undermining schizophrenia treatment—and what must change.

Community pharmacists emerged as the critical clinical link in the modern patient care continuum

Natalie Bellini, DNP, FNP-BC, BC-ADM, breaks down how updated ADA guidelines have broadened eligibility for continuous glucose monitors, automated insulin delivery systems, and continuous ketone monitoring.

If approved for this indication, finerenone would become the first nonsteroidal mineralocorticoid receptor antagonist indicated for adults with type 1 diabetes and CKD.

On World Schizophrenia Day, a psychiatric pharmacist details how EHR fragmentation drives medication errors in schizophrenia care, and why provider recognition is essential to fixing it.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, explains how pharmacists should approach continuous glucose monitoring (CGM) report review and explains why individualized patient education is key.

Eli Lilly's investigational triple hormone receptor agonist achieved average weight loss of up to 70.3 lb over 80 weeks.

A retrospective cohort study determined that individuals who consumed less than 1.0 g/kg/day of protein had significantly better kidney-related outcomes over 15 years of follow-up.

Nicole C. Pezzino, PharmD, BCACP, CDCES, explains why reimbursement gaps, workflow constraints, and the emotional burden of wearing a continuous glucose monitor (CGM) are limiting CGM success and how pharmacists can improve outcomes.

Prior authorizations, injection site shortages, and care transition failures are undermining LAI antipsychotic adherence in patients with schizophrenia, one pharmacist explains.

Three psychiatric pharmacists highlight trends in psychiatric pharmacotherapy that were shared at the AAPP 2026 Annual Meeting.

A large analysis found that measurable declines in processing speed, global cognition, and executive function began up to 8 years before a cardiovascular event.

Natalie Bellini, DNP, FNP-BC, BC-ADM, explains why continuous glucose monitor (CGM) persistence so often breaks down after initiation and how pharmacists can intervene at the point of dispensing.

The FDA approved baxdrostat based on meaningfully positive results from the phase 3 BaxHTN trial.

Pharmacy technicians are vital to obesity care, improving access, adherence, and patient engagement in increasingly complex treatment pathways.

Clinical pharmacists Andrew Willeford and Laura Velazquez explore the paradigm shift in oHCM management, highlighting best practices for pharmacist-led clinical workflows in health-system practice.

Patients with CKD and GERD who initiated P-CABs had a 37% lower risk of needing renal replacement therapy.

Data from the STEP UP trial support semaglutide 7.2 mg as a well-tolerated option for patients who need greater weight reduction.

The commissioner's sudden departure leaves the agency navigating a crowded agenda of unresolved policy questions—many with direct implications for pharmacists and their patients.

Makary's 13-month tenure ends after clashes with the Trump administration over flavored vape approvals, mifepristone policy, and broader agency management.

Integrated pharmacist-led care models help to improve diabetes outcomes, expand CGM use, and reduce costs through proactive, multidisciplinary patient management.